October 21, 2021

Focus on decentralized clinical trials (DCTs) has taken a massive leap over the course of the pandemic. COVID-19 forced an accelerated use of telemedicine, home health options and digital applications to keep studies running. Emerging from COVID-19, the use of decentralized solutions continues to rise worldwide. Although somewhat slower to adopt, the Asia-Pacific region has seen a dramatic shift in elements critical to implementation of decentralized solutions, including emerging clarity in regulatory guidance and greater acceptance of home health services, which will serve as important drivers of accelerated future use of DCT. 

As APAC developers continue to explore opportunities to incorporate DCT into their clinical strategies, understanding what is working well in other markets – whether it be with the intent of leveraging to bring their asset into those markets or with an eye toward adapting these best practices to the unique APAC landscape – is key to success. 

 

Watch this webinar recording to: 

 

  • Learn implementation tactics and benefits of DCT in the US and Europe 
  • Review case studies illustrating best practices for DCT implementation – and how these can be applied to APAC trials 
  • Understand critical regulatory, site-specific and cultural implications to consider when applying DCT in APAC 
Scroll to Page Bottom Form 
Enabled